Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10644144 | 0.86 | PPARA (0.50) | F2RL1FFAR1SMN1; SMN2PPARAPPARD | |
| SCHEMBL25596239 | 0.83 | BLM (0.47) | — | |
| SCHEMBL22033168 | 0.81 | F2RL1 (0.46) | F2RL1FFAR1SMN1; SMN2PPARAPPARD | |
| SCHEMBL28136422 | 0.77 | LDHA (0.53) | F2RL1SMN1; SMN2PPARAPPARDLDHA | |
| SCHEMBL25045888 | 0.75 | PPARA (0.59) | F2RL1FFAR1PPARAALOX5CALM1 | |
| SCHEMBL1236959 | 0.75 | CALM1 (0.53) | F2RL1FFAR1SMN1; SMN2PPARAALOX5 | |
| SCHEMBL18065719 | 0.75 | NPC1 (0.58) | F2RL1NPC1RAB9AALOX5 | |
| SCHEMBL11203493 | 0.75 | FFAR1 (0.51) | F2RL1FFAR1SMN1; SMN2LDHANPC1 | |
| SCHEMBL28184932 | 0.74 | F2RL1 (0.53) | F2RL1FFAR1SMN1; SMN2RAB9AALOX5 | |
| SCHEMBL10642941 | 0.74 | CYP19A1 (0.54) | SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | F2RL1 2433/4885FFAR1 4644/4885SMN1; SMN2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.